SPECIAL COUNCIL REVIEW

Applications from PI/PDs with greater than \$1.5M Annual Total Costs of NIH Support

Special Council Review

- FY2013 HHS Budget Brief states: "[NIH] will also establish a process for additional scrutiny and review by the Institute or Center Advisory Council of awards to any principal investigator with existing grants of \$1.5 million or more in total costs."
- Special Council Review (SCR) of pending applications from PI/PDs with >\$1.5M Total Annual Costs of NIH Support. See
 http://grants.nih.gov/grants/guide/notice-files/NOT-OD-12-110.html
- Pilot exercise during May/June 2012 Council meetings
 - "Review of review process"
 - DPCPSI will only see DCM*/ORIP cases
- IC-specific variations may be developed in consultation with individual Councils
 - NIH-wide policy to be developed

^{*}Only Division of Comparative Medicine (DCM) has RPG programs and applications



What Receives Special Council Review?

- Competing Research Project Grants (RPGs)
- Excluded:
 - P01s (unless all PI/PDs exceed threshold)
 - Other multi-component RPGs (unless all PI/PDs exceed threshold)
 - Multi-PI/PD applications (unless all PI/PDs exceed threshold)
 - RFAs



Information provided to Council for SCR by NIH

- PI/PD's active portfolio (incl. end dates, budget)
- Thematic difference and innovation of proposed new work
- Field of research (e.g. clinical trials are expensive) and program priority
- Public health priority
- Degree to which restricting or preventing award would limit collaborations




Factors to Consider

Program Staff

- Scientific merit (e.g., score, reviewer comments)
- Whether application contributes significantly to the DCM mission
- Program priorities, portfolio balance
- Availability of funds (e.g., DCM considers that competing funding opportunities have a higher priority)

Council

- Reviews list of competing awards
- Reviews justification and recommendation from NIH staff (e.g., consideration for funding)
- Votes to concur/not concur with staff recommendation
- Council action will be documented





Pilot – DCM/ORIP application

- Specific example Hypothetical Case
- Pl's Total Funding (FY12): \$1.6M
- New R21 application (FY12): \$222,000 TC
- Title: Developing HLA expressing mouse lines



COUNCIL DISCUSSION

